A microneedle-based delivery system for broad-protection seasonal influenza A DNA nanovaccines
Source abstract
Abstract
Seasonal influenza A viruses continue to pose a public health threat, and current vaccines are not sufficiently effective because of virus mutation. There is an urgent need to develop a broad-protection influenza A vaccine. Our team previously designed potential universal hemagglutinin (HA) sequences against seasonal influenza A H1N1 and H3N2 (mH1 and mH3, respectively) through a mosaic strategy. In this study, we construct DNA vaccines by linking the antigens mH1 and mH3 via internal ribosome entry sites and then wrap the DNA with the deoxycholic acid-modified polyetherimide to form DNA nanovaccines. A microneedle is used to deliver DNA nanovaccines, and the data show that better cellular and cross-reactivity and protective immunity are induced compared with the intramuscular injection method. These results suggest that microneedle-based delivery of DNA nanovaccines could be a promising platform for development of a broad-protection influenza vaccine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Influenza Virus Research Studies · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (70)
Show source-provided references
1. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study10.1016/S0140-6736(17)33293-2 ↗
2. Origin and progress of the 1968-69 Hong Kong influenza epidemic
3. Pandemic influenza in 1957; review of international spread of new Asian strain10.1001/jama.1958.02990100028006 ↗
4. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection10.1073/pnas.1921186117 ↗
5. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic10.1353/bhm.2002.0022 ↗
6. Comparative Co-evolution analysis between the HA and NA genes of influenza A virus
7. New world bats harbor diverse influenza A viruses10.1371/journal.ppat.1003657 ↗
8. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, february 201810.15585/mmwr.mm6706a2 ↗
9. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness10.2807/1560-7917.ES.2018.23.5.18-00035 ↗
10. Vector design for improved DNA vaccine efficacy, safety and production10.3390/vaccines1030225 ↗
11. Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine
12. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants10.1038/nm1461 ↗
13. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants10.7554/eLife.78633 ↗
14. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains10.1038/s41541-019-0126-4 ↗
15. Dengue mosaic vaccines enhance cellular immunity and expand the breadth of neutralizing antibody against all four serotypes of dengue viruses in mice10.3389/fimmu.2019.01429 ↗
16. Intradermal SynCon® ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers10.1093/infdis/jiz132 ↗
17. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial10.1016/S1473-3099(19)30266-X ↗
18. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial10.1016/j.eclinm.2020.100689 ↗
19. India's DNA COVID vaccine is a world first - more are coming10.1038/d41586-021-02385-x ↗
20. Large animal models for vaccine development and testing10.1093/ilar/ilv009 ↗
21. DNA vaccine delivery and improved immunogenicity10.21775/cimb.022.129 ↗
22. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults10.1056/NEJMoa2031499 ↗
23. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells10.1038/s41587-020-0741-7 ↗
24. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 110.1016/j.jpeds.2020.05.044 ↗
25. Human immune responses to adeno-associated virus (AAV) vectors10.3389/fimmu.2020.00670 ↗
26. Quaternized chitosan-coated liposomes enhance immune responses by co-delivery of antigens and resveratrol10.1016/j.ijpharm.2022.122277 ↗
27. Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination10.1016/j.jconrel.2022.10.002 ↗
28. New insights on the mechanism of polyethylenimine transfection and their implications on gene therapy and DNA vaccines10.1016/j.colsurfb.2021.112219 ↗
29. Cell-penetrating peptides: breaking through to the other side10.1016/j.molmed.2012.04.012 ↗
30. Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge10.1016/j.vaccine.2022.09.008 ↗
31. Intradermal delivery of mRNA using cryomicroneedles10.1016/j.actbio.2022.06.015 ↗
32. Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine10.1038/s41541-022-00443-7 ↗
33. An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination10.1073/pnas.2110817118 ↗
34. Polymeric microneedle-mediated sustained release systems: design strategies and promising applications for drug delivery
35. Smart microneedles for therapy and diagnosis10.34133/2020/7462915 ↗
36. Christmas tree-shaped microneedles as FOLFIRINOX spatiotemporal delivery system for pancreatic cancer treatment10.34133/2022/9809417 ↗
37. Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency10.1016/j.apsb.2022.04.015 ↗
38. Evaluation of a novel DNA vaccine double encoding somatostatin and cortistatin for promoting the growth of mice10.3390/ani12121490 ↗
39. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-1910.1021/acsnano.1c03252 ↗
40. Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier10.1016/j.jconrel.2013.02.031 ↗
41. Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells10.1007/s11095-012-0750-4 ↗
42. Plasmid-DNA delivery by covalently functionalized PEI-SPIONs as a potential 'magnetofection' agent10.3390/molecules27217416 ↗
43. Core-shell structured chitosan-polyethylenimine nanoparticles for gene delivery: improved stability, cellular uptake, and transfection efficiency10.1002/mabi.202200314 ↗
44. T follicular helper cell differentiation, function, and roles in disease10.1016/j.immuni.2014.10.004 ↗
45. T follicular regulatory cells10.1111/imr.12411 ↗
46. Progress towards the development of a universal influenza vaccine10.3390/v14081684 ↗
47. An antibody that prevents the hemagglutinin low pH fusogenic transition10.1006/viro.2001.1320 ↗
48. Role of the B-cell response in recovery of mice from primary influenza virus infection10.1111/j.1600-065X.1997.tb01009.x ↗
49. Recent advances in nanoparticle-based cancer drug and gene delivery10.1016/bs.acr.2017.11.003 ↗
50. Applications of nanoparticle systems in gene delivery and gene therapy10.3109/21691401.2014.971805 ↗
51. Needle-free epidermal powder immunization10.1586/14760584.1.3.265 ↗
52. Enabling skin vaccination using new delivery technologies10.1007/s13346-010-0005-z ↗
53. Skin immunization made possible by cholera toxin10.1038/36014 ↗
54. Needle-free vaccine injection10.1007/978-3-642-00477-3_7 ↗
55. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies10.1146/annurev-chembioeng-073009-100948 ↗
56. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen10.1016/j.actbio.2019.07.003 ↗
57. Polyplex-releasing microneedles for enhanced cutaneous delivery of DNA vaccine10.1016/j.jconrel.2014.01.016 ↗
58. Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles10.1016/j.jconrel.2017.04.027 ↗
59. Microneedle-based ocular drug delivery systems - recent advances and challenges10.3762/bjnano.13.98 ↗
60. Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment10.7150/thno.69999 ↗
61. Genetic background and the dilemma of translating mouse studies to humans10.1016/j.immuni.2007.12.008 ↗
62. Immune-cell lineage commitment: translation from mice to humans10.1016/j.immuni.2007.05.011 ↗
63. Construction of a bicistronic vector for the co-expression of two genes in Caenorhabditis elegans using a newly identified IRES10.2144/000113821 ↗
64. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type Ataxin1 levels10.1016/j.cell.2015.02.012 ↗
65. The Streptococcus mutans irvA gene encodes a trans-acting riboregulatory mRNA10.1016/j.molcel.2014.11.003 ↗
66. MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine10.1016/j.biomaterials.2013.11.019 ↗
67. Correction to: histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling10.1186/s12943-018-0885-y ↗
68. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment10.1021/nn4047925 ↗
69. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting10.1126/sciadv.aba0776 ↗
70. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination10.1128/JVI.02035-08 ↗